The National Trial Lawyers
BBB
Million Dollar Advocates Forum
10 Best
Asbestos Mesothelioma Trial Lawyers - Top 10
Best Attorneys of America
Veteran Approved
Americas Top 100
Lawyers of Distinction
The American Association For Justice
Best Law Firms Of America
Top American Lawyers

Articles Posted in Mesothelioma Medical

A recent Duke University study published in The American Journal of Surgical Pathology examined hundreds of women diagnosed with diffuse mesothelioma, looking to an analyzing trends among the group which could eventually shed light on new treatment and detection methods. One of the key findings in the mesothelioma cancer study found that women with objective markers were diagnosed with pleural mesothelioma and that their average age of diagnosis was older compared to those diagnosed with another common type of the cancer, peritoneal mesothelioma.

The mesothelioma cancer study, which was a continuation study of an ongoing study by Duke University, examined 354 female mesothelioma patients of which the overwhelmingly majority were known to have been exposed to asbestos. The authors state that this exposure came from household contact, primarily from a family member who would have been exposed to asbestos fibers in an industrial setting. Of those studied, 275 patients had a pleural mesothelioma diagnosis which corresponds to linings of tissue surrounding the lungs and 79 cases were those of peritoneal mesothelioma which affects tissue linings around the abdominal cavity.

The researchers found that survival rates were longer for those with epithelial subtypes of peritoneal mesothelioma, though their average age of diagnosis was younger at 52 years of age compared to 62 years of age for those diagnosed with pleural mesothelioma. Further, researchers found that tremolite asbestos was a common form of the mineral which the patients were exposed to, followed by amphibole asbestos – considered one of the most deadly forms of the mineral. Some of these types of asbestos are found in cosmetics products such as talcum powder.

The Food and Drug Administration (FDA) recently announced that it will host a public forum discussing the methods used to test for asbestos fibers in talc-based products, as well as the terminology and criteria that can be used to measure the carcinogen in consumer products. During that forum, the FDA will discuss preliminary recommendations from the Interagency Working Group on Asbestos in Consumer Products (IWGAC)—an interagency working group formed in 2018 to support the development of standardized testing methods for asbestos and other harmful particles.

The purpose of the IWGAC is to address the terminology and definitions of asbestos, recommend improvements for measuring asbestos in talc-based products, and recommend testing standards to test these products. The FDA forum comes two-years after the agency first began investigating reports of asbestos in talcum powder products, during which time it tested 50 such products and confirmed the presence of asbestos in some. One of those examinations in October 2019 revealed the presence of asbestos fibers in a lot of Johnson & Johnson’s Baby Powder, which caused the company to voluntarily recall 33,000 bottles of the iconic product.

Specifically, the IWGAC recommends adopting the term elongate mineral particles (EMP) to be “any mineral particle with a minimum aspect ratio of 3:1,” as to resolve ambiguity and disagreement of asbestos vs non-asbestos identification. Testing laboratories report all EMP having a length of over 500 nm and that testing methods specify reportable EMP identified as certain types of asbestos.

A recent study conducted by an international team of pathologists has reportedly identified a new protein which is often found in the tumor cells of patients diagnosed with pleural mesothelioma, a rare and deadly form of lung cancer which commonly affects the thin lining of tissue surrounding the lungs. With the discovery, researchers hope that doctors can make a more accurate prognosis for their patients and craft more effective and targeted treatment options to help these individuals live longer, more comfortable lives.

Published in The Journal of Pathology, the study found that the presence of protein CD70 correlates with a worse prognosis in patients with malignant pleural mesothelioma through immune evasion and enhanced invasiveness. The study was led by researchers at Aichi Medical University School of Medicine in Nagakute, Japan, with contributions from doctors based in the U.S., Poland, and Germany.

In the paper, the authors determined that about 20% of the mesothelioma tumor cells examined showed high levels of the CD70 protein, which resulted in a median survival of only six and a half months compared to a survival rate of a year and a half for patients without the over expression of the protein. Researchers believe these findings may explain the significant differences in survival periods between patients with the disease. The same protein has been studied in other serious forms of cancer, including certain types of kidney cancers and brain cancers.

When patients are diagnosed with a debilitating disease such as cancer, their focus often immediately shifts towards whether or not they will require surgery to treat the disease and what, if any, are the least invasive and most effective treatment options. Some forms of cancer can be treated without surgery, using radiation or chemotherapy, if caught in the early stages, while others leave patients with limited treatment options that may leave surgery as the only course of action.

A recent European study compared surgical treatments in patients diagnosed with malignant pleural mesothelioma, a rare and deadly form of cancer affecting the thin lining of tissue surrounding the lungs. The researchers compared data of two types of treatments performed from 1999 through 2018, pleurectomy/decortication (P/D) and extrapleural pneumonectomy (EPP) to see if patients fared better with one treatment over the other in terms of survival.

Mesothelioma has a particularly long latency period, which is the time between exposure to a carcinogen and when a diagnosis is actually made. The disease’s latency period can be anywhere from 20 years to 50 years, which can leave patients with especially limited treatment options and make surgery the only treatment available to prolong the individual’s lifespan.

A new scientific report by the American College of Occupational and Environmental Medicine suggests a strong and credible link between the use of asbestos-contaminated talcum powder products and developing malignant mesothelioma. The case study was published in the organization’s Journal of Occupational and Environmental Medicine, looking into the cases of 33 patients confirmed to have malignant mesothelioma and whose only known exposure to asbestos may have come from using tainted talcum powder in cosmetic products.

All of the patients in the study are involved in talcum powder cancer lawsuits against cosmetics companies. The authors went into greater detail on the conditions of six patients who underwent tissue analysis showing asbestos fibers consistent with those that would be found in contaminated talcum powder. The study’s authors pointed out that the asbestos fibers discovered were not consistent with the types of asbestos fibers which would be found in industrial settings, such as insulation or other building materials.

The report is just the latest in a series of bad news for Johnson & Johnson, which currently faces an estimated 14,000 talcum powder cancer lawsuits accusing the company of knowingly manufacturing and marketing dangerous talc-based products. Thus far, juries in state and federal courts have awarded plaintiffs over $5 billion in combined compensation in trials against Johnson & Johnson, which continues to litigate cases and deny responsibility for any wrongdoing.

A pair of recent studies suggest that a certain treatment may be able to help treat mesothelioma, a rare and deadly form of cancer that often affects the thin lining of tissue surrounding the lungs, but may also affect other parts of the body. The treatment, called talc pleurodesis, is a surgical procedure to help prevent pleural effusions, which is when fluid builds around the lungs, making it hard for the patient to breathe and allow the disease to spread.

In a recent study published by the Journal of Thoracic Disease, researchers found that the procedure improves survival rates of patients better than some other lung fluid treatments. The results further suggest that the treatment, which is less invasive than others, may be a better quality of life option than more aggressive surgery to remove tumors surrounding the lungs.

The study, conducted by Dr. Emanuela Taioli of the Institute of Translational Epidemiology at Ichan, examined almost 50 other studies focused on the survival rates of patients who underwent talc pleurodesis compared to those who underwent surgery. Research showed that on average, the survival rate of patients treated with talc pleurodesis was 14 months, compared to 17 months for those who underwent invasive surgery, like pleurectomy and decortication, and 24 months for even more aggressive surgeries like extrapleural pneumonectomy.

A Memphis, Tennessee hospital recently began using a first of its kind electric therapy treatment approved by the Food and Drug Administration (FDA) to treat the progression of mesothelioma, a rare and deadly form of lung cancer caused by exposure to asbestos fibers. “Because it is such a rare cancer, there has been little research opportunities to advance science and treatment of mesothelioma,” said Dr. Moon Fenton, West Cancer Center hematologist while speaking to local media.

For decades, doctors treated mesothelioma through a combination of surgery, radiation treatment, and chemotherapy. Now, doctors will have access to a fourth treatment option via the NovoTTF-100. The devices functions by attaching three to the front and back of the patient’s chest and sending electric fields into the body to target and disrupt mesothelioma cancer cells from growing and spreading, all while allowing healthy cells to remain intact.

“We are looking at 97% disease control at year one. So, patients who are using this technology in addition to the chemotherapy actually have stable disease or great response to treatment,” said Dr. Fenton in a local NBC interview. “This treatment is not invasive, and has minimal side effects.” Patient’s at Dr. Fenton’s hospital, West Cancer Center, will wear the device for 18 hours per day to treat mesothelioma.

Mesothelioma is a rare and deadly form of cancer caused by exposure to asbestos fibers. Asbestos is a naturally occurring mineral once used in a variety of industrial, commercial, and military applications mostly for its ability to be molded into almost any shape, as well as its heat-resistant properties. Unfortunately, the widespread use of asbestos attributes to 3,000 annual diagnoses even to this day.

Asbestos was once commonly used in vinyl flooring tiles, home insulation, auto parts-such as brakes and gaskets, and even in everyday appliances like ovens. The mineral found extensive use in industrial applications for pipefitting, steamfitting, and other heavy-duty insulation and gasket-making applications. Asbestos was once widely used in military applications aboard Navy ships in engine rooms.

One of the main complications with mesothelioma is its latency period – the time between exposure and diagnosis, which can be anywhere from 20 years to 50 years, leaving patients with diminished treatment options upon diagnosis. The type of mesothelioma discovered can also further complicate matters. The three main types of mesothelioma are:

A recent report published in CA: A Cancer Journal for Clinicians shed some revealing light on cancer statistics across the globe, including the most commonly diagnosed types of cancers and their mortality rates across genders. According to the report, compiled by researchers employed by the American Cancer Society, lung cancer remains the most commonly diagnosed form of cancer and the one with the highest mortality rate overall, particularly among men but also among women, worldwide.

Using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, the researchers found that there were an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. Across both sexes, instances of lung cancer accounted for 11.6% of the total cases and the leading cause of cancer death at 18.4% of the total cancer deaths.

Those mortality rates were closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality rate. The most common type of cancer and the one which has the highest mortality rate among men is lung cancer, followed by prostate cancer and colorectal cancer for incidence and liver and stomach cancer for mortality. Lung cancer is the third most commonly diagnosed form of cancer among women and the second highest in mortality.

Mesothelioma is a very rare, very aggressive form of cancer. While it affects only a few thousand people each year, its effects are often devastating. Chances of survivability are very low, the signs and symptoms are difficult to spot, and usually take decades to manifest.

Possibly the most distressing aspect of mesothelioma is that it is often incurable. Treatments are available, but due to the disease’s rarity, modern medicine has had few chances to study it on an in-depth level. If these symptoms and circumstances are familiar to you, schedule an appointment with your doctor.

Causes and signs of mesothelioma

Contact Information